REMARKS

Status of the Claims

Claims 4, 6, and 10-14 are pending in the present application. Claims 1-3, 5, and 7-9 have been cancelled without prejudice to or disclaimer of the subject matter contained therein. Claims 1-3 and 7-9 are cancelled due to the restriction requirement. Applicants reserve the right to file continuing applications directed to the cancelled subject matter.

Claims 4 and 6 have been amended, and new claims 10-14 have been added. Support for the new and amended claims may be found in the original specification and claims inlouding, for example, on lines 28-30 of page 27, lines 1-10 and 20-30 of page 29, line 14 of page 30 through 9 of page 31, lines 20-26 of page 31, and lines 2-6 of page 35. No new matter has been added by way of amendment.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

Kathy L. Coulty

Kathryn L. Coulter Patent Agent

Registration No. 45,889

Date: <u>June 6, 2007</u> GlaxoSmithKline

Five Moore Drive, PO Box 13398

Research Triangle Park, North Carolina 27709

Telephone: (919) 483-1467 Facsimile: (919) 483-7988